TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
TRINITY BIOTECH PLC
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Trinity Biotech's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| AI n M net Ltd. | 69,450,720 | 17.00% | 13D (active) amendment | Dec 8, 2025 |
| DAYLI Partners, Inc. | 69,450,720 | 18.00% | 13D (active) amendment | Dec 17, 2024 |
| MiCo IVD Holdings, LLC | 69,450,720 | 17.00% | 13D (active) amendment | Dec 2, 2025 |
| Perceptive Credit Advisors LLC | 3,424,019,957 | 9.90% | 13D (active) amendment | Apr 30, 2026 |
| Perceptive Advisors LLC | 1,463,058,248 | 9.90% | 13D (active) amendment | Jan 22, 2026 |
| Novus Diagnostics Ltd. | 1,119,988 | 5.99% | 13G (passive) | Dec 23, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Murphy | Interim CFO | – | – | Apr 3, 2026 |
| Ronan O'Caoimh | Director | 486,208 | 0.13% | Apr 8, 2026 |
| John Gillard | Director | 10,000 | 0.00% | Apr 8, 2026 |
| John Paul Tivnan | Director | – | – | Apr 3, 2026 |
| Andrew Omidvar | Director | – | – | Apr 3, 2026 |